Oric Pharmaceuticals, Inc. (ORIC) Upgraded to Buy: What Does It Mean for the Stock?Zacks Investment Research • 10/16/23
ORIC Pharmaceuticals to Participate in the 2023 Cantor Global Healthcare ConferenceGlobeNewsWire • 09/20/23
ORIC Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operational UpdatesGlobeNewsWire • 08/10/23
ORIC Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational UpdatesGlobeNewsWire • 05/08/23
ORIC Pharmaceuticals to Participate in the H.C. Wainwright BioConnect Investor ConferenceGlobeNewsWire • 04/25/23
ORIC Pharmaceuticals Presents Promising Preclinical Data on Two Programs at the 2023 American Association for Cancer Research (AACR) Annual MeetingGlobeNewsWire • 04/18/23
ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operational UpdatesGlobeNewsWire • 03/16/23
ORIC Pharmaceuticals Announces Multiple Presentations at the 2023 American Association for Cancer Research (AACR) Annual MeetingGlobeNewsWire • 03/14/23
ORIC Pharmaceuticals to Participate in the Oppenheimer 33rd Annual Healthcare ConferenceGlobeNewsWire • 03/06/23
ORIC Pharmaceuticals Provides Corporate Update and Highlights Key Upcoming MilestonesGlobeNewsWire • 01/09/23
ORIC Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/03/23
ORIC Pharmaceuticals Announces Clinical Development Collaboration with Pfizer for ORIC-533 in Multiple Myeloma and Concurrent $25 Million Equity Investment by PfizerGlobeNewsWire • 12/21/22
ORIC Pharmaceuticals Presents Preclinical Data Demonstrating ORIC-533 as a Potential Best-in-Class CD73 Inhibitor at the 64th American Society of Hematology (ASH) Annual MeetingGlobeNewsWire • 12/13/22
ORIC Pharmaceuticals to Present at the Jefferies London Healthcare ConferenceGlobeNewsWire • 11/08/22